Pharmaceuticals

Growth Of The Yellow Fever Vaccine Due To Increasing International Travel Is Contributing To Changes In The Zynlonta Market

May 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Zynlonta Market From 2026 To 2030?

The historical growth can be linked to a surge in hematological cancer cases, along with an increase in the inefficacy of standard chemotherapy. Contributing factors also include the proliferation of specialized oncology centers, enhanced diagnostic abilities for specific lymphoma subtypes, and the expanding clinical integration of ADC therapies.

The anticipated expansion within the forecast period is driven by several factors, including the heightened creation of advanced antibody-drug conjugates, an increased need for tailored cancer therapies, the broadening of specialized cancer drug development pipelines, escalating financial commitments in biological cancer medications, and the wider application of combined cancer treatment approaches.

Significant developments anticipated in the forecast period encompass a greater uptake of antibody-drug conjugate therapies, an increase in targeted therapeutic interventions for b-cell lymphomas, an intensifying concentration on precision oncology pharmaceuticals, the growth of oncology infusion services within hospitals, and a stronger focus on therapies for recurrent and resistant cancers.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20435&type=smp

Which Strong Drivers Are Impacting The Zynlonta Market Growth?

The increasing occurrence of lymphomas is anticipated to drive the expansion of the zynlonta market. Lymphomas are a category of cancers that originate in the lymphatic system, primarily affecting lymphocytes, a type of white blood cell found in lymph nodes, the spleen, bone marrow, and other lymphoid tissues. Several factors contribute to this growing prevalence, including an older demographic, compromised immune systems, exposure to environmental elements, viral infections, hereditary factors, and personal lifestyle decisions. Zynlonta serves as a specific treatment for recurrent or resistant large B-cell lymphoma (LBCL), working by directly targeting and eliminating cancerous B cells with a chemotherapy agent. As an illustration, the American Cancer Society, a non-profit organization based in the US, reported an increase in new lymphoma cancer cases, from an estimated 89,010 in 2022 to 89,380 in 2023. Consequently, the increased occurrence of lymphomas fuels the expansion of the zynlonta market.

What Segment Categories Shape The Zynlonta Market Segment Landscape?

The zynlonta market covered in this report is segmented –

1) By Indication: Diffuse Large B-Cell Lymphoma (DLBCL), High-Grade B-Cell Lymphoma, DLBCL Arising From Follicular Lymphoma

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End-User: Adult Patients, Geriatric Patients

Which Trends Are Influencing Demand In The Zynlonta Market?

A significant trend within the zynlonta market involves the creation of novel therapies, especially combination therapies, to enhance treatment effectiveness and improve patient outcomes in cancer care. Combination therapies denote the application of two or more treatments, such as drugs or other therapeutic methods, to amplify their efficacy and address various aspects of a disease. An example of this is the update provided in April 2024 by ADC Therapeutics, a Switzerland-based biotechnology company focused on pioneering antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. They shared developments concerning their LOTIS-7 clinical trial, which is examining Zynlonta (loncastuximab tesirine-lpyl) when combined with bispecific antibodies like glofitamab or mosunetuzumab. The objective of this trial is to treat heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).

Who Are The Companies Operating Across The Zynlonta Market Value Chain?

Major companies operating in the zynlonta market are ADC Therapeutics SA, Avid Bioservices Inc

Get The Full Zynlonta Market Report:

https://www.thebusinessresearchcompany.com/report/zynlonta-global-market-report

Which Region Dominates The Zynlonta Market By Market Share?

North America was the largest region in the zynlonta market in 2025. The regions covered in the zynlonta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Zynlonta Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/zynlonta-global-market-report

Browse Through More Reports Similar to the Global Zynlonta Market 2026, By The Business Research Company

Zinc Market Report 2026

https://www.thebusinessresearchcompany.com/report/zinc-global-market-report

Zinc Oxide Market Report 2026

https://www.thebusinessresearchcompany.com/report/zinc-oxide-global-market-report

Zinc Citrate Market Report 2026

https://www.thebusinessresearchcompany.com/report/zinc-citrate-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795